BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
Biomarin Pharmaceutical stock last closed at $84.90, up 0.62% from the previous day, and has decreased 7.33% in one year. It has overperformed other stocks in the Biotechnology industry by 0.01 percentage points. Biomarin Pharmaceutical stock is currently +15.24% from its 52-week low of $73.68, and -14.72% from its 52-week high of $99.56.
At the moment, there are 190.38M shares of BMRN outstanding. The market value of BMRN is $16.16B. In the last 24 hours, 1.19M BMRN shares were traded.
How to Buy Biomarin Pharmaceutical Stock
Not sure how to invest in Biomarin Pharmaceutical stock? Here's how.
Choose where to buy Biomarin Pharmaceutical stock: You need to pick an online brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you determine where to buy Biomarin Pharmaceutical stock.
Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
Put funds into your investment account: Select your payment method and add your details.
Research Biomarin Pharmaceutical stock: The Biomarin Pharmaceutical ticker symbol is BMRN. Is Biomarin Pharmaceutical stock a good investment? Should you buy shares of BMRN? How do BMRN's underlying business fundamentals look? Do top analysts think Biomarin Pharmaceutical is a good buy? Why has BMRN's stock price moved recently? (Hint: Our stock research tools can help you decide if BMRN is a good stock to buy).
Make your BMRN buy order: Decide if you will purchase BMRN shares at the current market price or use a limit order to buy BMRN shares at a given price.
Get notifications regarding your BMRN investment: Create a watchlist to important notifications about your new investment in Biomarin Pharmaceutical shares.
Step 1: Choose where to buy Biomarin Pharmaceutical stock
You need an online brokerage account in order to access the NASDAQ market and buy BMRN stock.
A brokerage account allows you to buy and sell a number of financial instruments, including stocks, bonds, mutual funds, and ETFs.
Our recommended brokerage: eToro
We believe that eToro is the best stock brokerage. Here's why:
Invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
Access to global markets: From Technology to Healthcare, New York to London — you can fill your portfolio with stocks from the world's top exchanges.
Social investing: eToro has a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by opening an account with eToro today.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Open your brokerage account
Now that you've selected your brokerage, you'll need to fill out some personal info so you are able to buy BMRN stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Research Biomarin Pharmaceutical stock
Once you have decided on the best place to buy Biomarin Pharmaceutical stock, it's absolutely critical to research their stock prior to investing, so you actually understand the risk as well as the upside.
Biomarin Pharmaceutical Metrics
BMRN Price
$84.90
1w %
0.98%
1y %
-7.33%
5y %
16.86%
P/E
62.89x
P/B
3.06x
P/S
6.24x
PEG
1.36x
Revenue
$2.59B
Earnings
$256.59M
Fore. Rev. Growth
10.27%
Fore. Earn. Growth
46.28%
Market Cap
$16.16B
Next Earnings
Oct 30, 2024
Next Dividend
N/A
Biomarin Pharmaceutical Fundamentals
WallStreetZen was built to help part-time investors perform more accurate fundamental analysis quickly.
BMRN's operating cash flow of $328.86M allows it to safely service it's debt of $1.09B.
BMRN profit margin has gone up from 4.5% to 9.9% in the past year.
There are more short-term assets than long-term liabilities on the BMRN balance sheet.
BMRN earnings of $315.68M is not enough to cover its interest payments.
There are more short-term assets than short-term liabilities on the BMRN balance sheet.
Total BMRN debt is lower than 5 years ago, relative to shareholder equity.
BMRN has a low debt to equity ratio of 0.34.
Is it a good time to buy Biomarin Pharmaceutical stock, according to analysts?
Out of 16 Equities analysts who give recommendations on BMRN, the consensus analyst rating on BMRN is a Strong Buy
It's important to keep in mind that analyst forecasts are not recommendations, nor are they financial advice.
Latest BMRN Analyst Upgrades/Downgrades
Christopher Raymond, a top 25% analyst from Piper Sandler maintains BMRN with a strong buy rating and raises their BMRN price target from $107.00 to $122.00, on Sep 5, 2024.
Piper Sandler's Christopher Raymond raised their price target on Biomarin Pharmaceutical (NASDAQ: BMRN) by 14% from $107 to $122 on 2024/09/05. The analyst maintained their Strong Buy rating on the stock.
Raymond attributed their price target hike on Biomarin Pharmaceutical to the company's presentation at its "highly anticipated" 2024 Investor Day on 2024/09/04.
Management announced its long-term guidance, which was "well above" expectations, the analyst told investors.
Raymond noted that Piper Sandler maintains its bullish view on the stock's setup.
Joon Lee, a top 3% analyst from Truist Securities maintains BMRN with a strong buy rating and lowers their BMRN price target from $140.00 to $118.00, on Sep 5, 2024.
Paul Matteis, a bottom 10% analyst from Stifel Nicolaus maintains BMRN with a strong buy rating and raises their BMRN price target from $112.00 to $115.00, on Aug 21, 2024.
William Pickering, a top 35% analyst from Bernstein upgrades BMRN to a buy rating and raises their BMRN price target from $94.00 to $110.00, on Aug 20, 2024.
Phil Nadeau, a top 13% analyst from TD Cowen maintains BMRN with a strong buy rating and lowers their BMRN price target from $125.00 to $120.00, on Aug 6, 2024.
Last year, BMRN earnings were $256.59M. Over the past 4 year, BMRN's earnings have gone up by 18.27% per year. This was faster than the Biotechnology industry average of 9.22%.
Last year, BMRN revenue was $2.59B. In the past five year, BMRN's revenue has gone up by 11.04% per year. This was slower than the Biotechnology industry average of 57.22%.
No, Biomarin Pharmaceutical doesn't provide an income stream by paying out dividends.
What do other investors have to say about BMRN?
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your BMRN buy order
There are two primary order types:
Market order: A market order is an order to buy or sell a security at the best possible price. Market orders are mostly fine for most investors.
Limit order: A limit order is an order to buy or sell a stock at a specific price (or better). If you want to be sure you're buying or selling at a given price, place a limit order.
Click the Open Trade button and your broker will place your order.
If you need additional help with buying stocks on eToro, click the helpful video below:
How much does it cost to buy one Biomarin Pharmaceutical share?
As of Sep 13, 2024, it costs $84.90 to buy one share of Biomarin Pharmaceutical stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.118 shares of BMRN.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.